862 VISCERAL ADIPOSITY INDEX, EXPRESSION OF ADIPOSE DYSFUNCTION, IS ASSOCIATED WITH SIGNIFICANT FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE

2011 ◽  
Vol 54 ◽  
pp. S344
Author(s):  
S. Petta ◽  
M. Amato ◽  
G. Licata ◽  
M. Barcellona ◽  
C. Cammà ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Visceral Adiposity ◽  
Visceral Adiposity Index ◽  
Alcoholic Fatty Liver ◽  
Significant Fibrosis ◽  
Adiposity Index ◽  
Adipose Dysfunction ◽  
Alcoholic Fatty Liver Disease

scholarly journals The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis—Systematic Review and Meta-Analysis

Biomedicines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1890
Author(s):  
Abdulrahman Ismaiel ◽  
Ayman Jaaouani ◽  
Daniel-Corneliu Leucuta ◽  
Stefan-Lucian Popa ◽  
Dan L. Dumitrascu
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Visceral Adiposity ◽  
Visceral Adiposity Index ◽  
Alcoholic Fatty Liver ◽  
Simple Steatosis ◽  
Adiposity Index ◽  
Alcoholic Fatty Liver Disease

(1) Background: In order to avoid a liver biopsy in non-alcoholic fatty liver disease (NAFLD), several noninvasive biomarkers have been studied lately. Therefore, we aimed to evaluate the visceral adiposity index (VAI) in NAFLD and liver fibrosis, in addition to its accuracy in predicting NAFLD and NASH. (2) Methods: We searched PubMed, Embase, Scopus, and Cochrane Library, identifying observational studies assessing the VAI in NAFLD and liver fibrosis. QUADAS-2 was used to evaluate the quality of included studies. The principal summary outcomes were mean difference (MD) and area under the curve (AUC). (3) Results: A total of 24 studies were included in our review. VAI levels were significantly increased in NAFLD (biopsy-proven and ultrasound-diagnosed), simple steatosis vs. controls, and severe steatosis vs. simple steatosis. However, no significant MD was found according to sex, liver fibrosis severity, simple vs. moderate and moderate vs. severe steatosis, pediatric NAFLD, and NASH patients. The VAI predicted NAFLD (AUC 0.767) and NASH (AUC 0.732). (4) Conclusions: The VAI has a predictive value in diagnosing NAFLD and NASH, with significantly increased values in adult NAFLD patients, simple steatosis compared to controls, and severe steatosis compared to simple steatosis.

scholarly journals The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis — Systematic Review and Meta-Analysis

2021 ◽  
Author(s):  
Abdulrahman Ismaiel ◽  
◽  
Ayman Jaaouani ◽  
Daniel-Corneliu Leucuta ◽  
Stefan-Lucian Popa ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Visceral Adiposity ◽  
High Density Lipoproteins ◽  
Visceral Adiposity Index ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Adiposity Index

Review question / Objective: The objective of the study was to compare the mean difference and AUROC of Visceral Adiposity Index (VAI) in NAFLD/NASH/liver fibrosis patients and controls in observational studies. Condition being studied: Nonalcoholic fatty liver disease (NAFLD) is a multi-system disease, being mainly a liver pathology involving excessive hepatic fat accumulation unrelated to alcohol consumption or other secondary causes of hepatic steatosis. It is an emerging cause of concern and increasing clinical burden, imposing a public health challenge. NAFLD is the most common chronic liver disease and is predicted to be the most common indication for a liver transplant in Western countries by 2030, owing to a prevalence of 25% worldwide. The visceral adiposity index (VAI) is a scoring system based on body mass index, triglycerides, high-density lipoproteins (HDLs), and waist circumferences (WCs).

Non-invasive Stratification of Non-Alcoholic Fatty Liver Disease by Whole-transcriptome Cell-free mRNA Characterization

2021 ◽  
Author(s):  
Naga Chalasani ◽  
Shusuke Toden ◽  
John J Sninsky ◽  
Richard P Rava ◽  
Jerome V Braun ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Healthy Subjects ◽  
Rna Seq ◽  
Alcoholic Fatty Liver ◽  
Significant Fibrosis ◽  
Non Invasive ◽  
Clinically Significant ◽  
Alcoholic Fatty Liver Disease

Hepatic fibrosis stage is the most important determinant of outcomes in patients with non-alcoholic fatty liver disease (NAFLD). There is an urgent need for non-invasive tests that can accurately stage fibrosis and determine efficacy of interventions. Here we describe a novel cf-mRNA-Sequencing approach that can accurately and reproducibly profile low levels of circulating mRNAs and evaluate the feasibility of developing a cf-mRNA-based NAFLD fibrosis classifier. Using separate discovery and validation cohorts with biopsy-confirmed NAFLD (n=176 and 59, respectively) and healthy subjects (n=23), we performed serum cf-mRNA RNA-Seq profiling. Differential expression analysis identified 2498 dysregulated genes between NAFLD and healthy subjects and 134 fibrosis-associated genes in NAFLD patients. Comparison between cf-mRNA and liver tissues transcripts revealed significant overlap of fibrosis associated genes and pathways indicating that the circulating cf-mRNA transcriptome reflects molecular changes in the livers of NAFLD patients. In particular, metabolic and immune pathways reflective of known underlying steatosis and inflammation were highly dysregulated in the cf-mRNA profile of patients with advanced fibrosis. Finally, we used an elastic net ordinal logistic model to develop a classifier that predicts clinically significant fibrosis (F2-4). In an independent cohort, the cf-mRNA classifier was able to identify 50% of patients with at least 90% probability of clinically significant fibrosis. We demonstrate a novel and robust cf-mRNA-based RNA-Seq platform for non-invasive identification of diverse hepatic molecular disruptions and for fibrosis staging with promising potential for clinical trials and clinical practice.

Sign in / Sign up

Export Citation Format

Share Document